Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab for Polyneuropathy Associated With MGUS
NCT06046287Phase 2Withdrawn
- Sponsor
- Georgetown University
- Start
- Sep 2025
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in polyneuropathy associated with monoclonal gammopathy of undetermined significance, sponsored by Georgetown University. Primary endpoint: INCAT Sensory Score change at 12 months. Planned start Sep 2025; status: withdrawn.
02
Drugs
daratumumab
03
Conditions
polyneuropathy associated with monoclonal gammopathy of undetermined significance
Beyond the preview
Go deeper on NCT06046287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06046287.